BRPI0815360A2 - Composto derivado de 4-pirimidinossulfamida, composição farmacêutica que o contem, uso e processo para pa preparação do composto - Google Patents
Composto derivado de 4-pirimidinossulfamida, composição farmacêutica que o contem, uso e processo para pa preparação do compostoInfo
- Publication number
- BRPI0815360A2 BRPI0815360A2 BRPI0815360-4A2A BRPI0815360A BRPI0815360A2 BR PI0815360 A2 BRPI0815360 A2 BR PI0815360A2 BR PI0815360 A BRPI0815360 A BR PI0815360A BR PI0815360 A2 BRPI0815360 A2 BR PI0815360A2
- Authority
- BR
- Brazil
- Prior art keywords
- pyrimidinosulfamide
- pharmaceutical composition
- composition containing
- derivative compound
- pair preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2007053292 | 2007-08-17 | ||
| IB2008052571 | 2008-06-26 | ||
| PCT/IB2008/053282 WO2009024906A1 (en) | 2007-08-17 | 2008-08-15 | 4-pyrimidinesulfamide derivative |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| BRPI0815360A2 true BRPI0815360A2 (pt) | 2015-02-10 |
| BRPI0815360A8 BRPI0815360A8 (pt) | 2017-12-26 |
| BRPI0815360B1 BRPI0815360B1 (pt) | 2018-12-04 |
| BRPI0815360B8 BRPI0815360B8 (pt) | 2021-05-25 |
Family
ID=40140023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0815360A BRPI0815360B8 (pt) | 2007-08-17 | 2008-08-15 | composto derivado de 4-pirimidinossulfamida, composição farmacêutica que o contem, uso e processo para a preparação do composto |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US8324232B2 (pt) |
| EP (1) | EP2190837B1 (pt) |
| JP (1) | JP5323075B2 (pt) |
| KR (1) | KR101528946B1 (pt) |
| CN (1) | CN101772494B (pt) |
| AR (1) | AR070018A1 (pt) |
| AU (1) | AU2008290234B2 (pt) |
| BR (1) | BRPI0815360B8 (pt) |
| CA (1) | CA2695511C (pt) |
| CY (2) | CY1113255T1 (pt) |
| DK (1) | DK2190837T3 (pt) |
| ES (1) | ES2394584T3 (pt) |
| FI (1) | FIC20240041I1 (pt) |
| FR (1) | FR24C1047I2 (pt) |
| HR (1) | HRP20120878T1 (pt) |
| HU (1) | HUS2400041I1 (pt) |
| IL (1) | IL203936A (pt) |
| LT (1) | LTPA2024534I1 (pt) |
| MA (1) | MA31702B1 (pt) |
| MX (1) | MX2010001837A (pt) |
| MY (1) | MY152281A (pt) |
| NL (1) | NL301304I2 (pt) |
| NO (1) | NO2024053I1 (pt) |
| NZ (1) | NZ583990A (pt) |
| PL (1) | PL2190837T3 (pt) |
| PT (1) | PT2190837E (pt) |
| RU (1) | RU2485116C2 (pt) |
| SI (1) | SI2190837T1 (pt) |
| TW (1) | TWI411437B (pt) |
| WO (1) | WO2009024906A1 (pt) |
| ZA (1) | ZA201001872B (pt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2907811A1 (en) * | 2014-02-14 | 2015-08-19 | Actelion Pharmaceuticals Ltd. | Process for manufacturing pyrimidine sulfamide derivatives |
| WO2017093903A1 (en) * | 2015-11-30 | 2017-06-08 | Laurus Labs Private Limited | An improved process for the preparation of macitentan |
| WO2017191565A1 (en) * | 2016-05-04 | 2017-11-09 | Shilpa Medicare Limited | Process for preparation of macitentan |
| KR102568472B1 (ko) | 2017-02-27 | 2023-08-18 | 이도르시아 파마슈티컬스 리미티드 | 엔도텔린 관련 질환의 치료를 위한 4-피리미딘술파미드 유도체와 활성 성분의 조합물 |
| KR20260037123A (ko) * | 2017-11-30 | 2026-03-17 | 이도르시아 파마슈티컬스 리미티드 | 엔도텔린 관련 질병의 치료를 위한 sglt-2 저해제와의 4-피리미딘설파미드 유도체의 병용 |
| CN108997223B (zh) * | 2018-08-09 | 2020-06-30 | 浙江先锋科技股份有限公司 | 5-(4-溴苯基)-4,6-二氯嘧啶的制备方法 |
| CA3123990A1 (en) | 2018-12-21 | 2020-06-25 | Actelion Pharmaceuticals Ltd | Pharmaceutical composition for the treatment of pulmonary arterial hypertension |
| TW202042818A (zh) | 2019-01-25 | 2020-12-01 | 瑞士商艾克泰聯製藥有限公司 | 用於治療慢性血栓性肺高血壓之醫藥組成物 |
| AU2020378025A1 (en) * | 2019-11-07 | 2022-06-23 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal form of Aprocitentan, preparation method therefor and use thereof |
| WO2021237004A1 (en) | 2020-05-21 | 2021-11-25 | Teva Pharmaceuticals International Gmbh | Solid state forms of aprocitentan and process for preparation thereof |
| CN114644595A (zh) * | 2020-12-19 | 2022-06-21 | 普济生物科技(台州)有限公司 | 阿普昔腾坦的无定型态、其药物组合物和用途 |
| WO2023111797A1 (en) * | 2021-12-17 | 2023-06-22 | Janssen Biotech, Inc. | Pyrimidine sulfamide derivatives and process for manufacturing them |
| AU2023276826A1 (en) | 2022-05-22 | 2025-01-09 | Idorsia Pharmaceuticals Ltd | Aprocitentan for the treatment of hypertension |
| US20250340520A1 (en) | 2022-05-25 | 2025-11-06 | Idorsia Pharmaceuticals Ltd | Crystalline forms of sodium (5-(4-bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-4-yl)(sulfamoyl)amide |
| CN119330888B (zh) * | 2024-10-25 | 2025-11-28 | 上海药坦药物研究开发有限公司 | 一种阿普昔腾坦的制备方法 |
| CN119528820B (zh) * | 2024-11-29 | 2025-10-10 | 浙江国邦药业有限公司 | 一种阿普昔腾坦的合成方法 |
| CN119528821B (zh) * | 2024-11-29 | 2025-10-10 | 浙江国邦药业有限公司 | 一种阿普昔腾坦的制备方法 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2801584A1 (de) | 1978-01-14 | 1979-07-19 | Bayer Ag | Halogensubstituierte pyrimidin (2)yl-thiono-thiol-phosphor(phosphon)- saeureester, verfahren zu ihrer herstellung und ihre verwendung als insektizide und akarizide |
| JPH04103525A (ja) | 1990-08-22 | 1992-04-06 | Sanwa Kagaku Kenkyusho Co Ltd | 難水溶性薬物の持続性製剤化方法 |
| RU2086544C1 (ru) | 1991-06-13 | 1997-08-10 | Хоффманн-Ля Рош АГ | Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина |
| TW394761B (en) | 1993-06-28 | 2000-06-21 | Hoffmann La Roche | Novel Sulfonylamino Pyrimidines |
| US5523204A (en) | 1993-12-10 | 1996-06-04 | Becton Dickinson And Company | Detection of nucleic acids in cells by strand displacement amplification |
| WO1996016963A1 (de) | 1994-11-25 | 1996-06-06 | F. Hoffmann-La Roche Ag | Sulfonamide und deren verwendung als heilmittel |
| TW313568B (pt) | 1994-12-20 | 1997-08-21 | Hoffmann La Roche | |
| US5739333A (en) | 1995-05-16 | 1998-04-14 | Tanabe Seiyaku Co., Ltd. | Sulfonamide derivative and process for preparing the same |
| TW442301B (en) | 1995-06-07 | 2001-06-23 | Sanofi Synthelabo | Pharmaceutical compositions containing irbesartan |
| WO1997022595A1 (en) | 1995-12-20 | 1997-06-26 | Yamanouchi Pharmaceutical Co., Ltd. | Arylethenesulfonamide derivatives and drug composition containing the same |
| US20010014352A1 (en) | 1998-05-27 | 2001-08-16 | Udit Batra | Compressed tablet formulation |
| TWI284642B (en) | 1999-01-18 | 2007-08-01 | Hoffmann La Roche | Novel heterocyclic sulfonamides |
| DE60037308T2 (de) | 1999-09-03 | 2008-10-30 | Actelion Pharmaceuticals Ltd. | Bis-sulfonamiden |
| CN1407973A (zh) | 1999-12-22 | 2003-04-02 | 埃科特莱茵药品有限公司 | 丁炔二醇衍生物 |
| US20040062803A1 (en) | 1999-12-22 | 2004-04-01 | Hedden David B. | Sustained-release formulation of a cyclooxygenase-2 inhibitor |
| HUP0203935A3 (en) | 1999-12-31 | 2006-02-28 | Encysive Pharmaceuticals Inc H | Sulfonamides and derivatives thereof that modulate the activity of endothelin, pharmaceutical compositions containing them and their use |
| AU2001263850A1 (en) | 2000-04-20 | 2001-11-07 | Actelion Pharmaceuticals Ltd | Pyrimidine-sulfonamides having endothelin-antagonist activity |
| AU2001265871A1 (en) | 2000-04-25 | 2001-11-07 | Actelion Pharmaceuticals Ltd | Substituted sulfonylaminopyrimidines |
| JP2001335469A (ja) | 2000-05-26 | 2001-12-04 | Lion Corp | 固体製剤の製造方法 |
| JP2004501191A (ja) | 2000-06-28 | 2004-01-15 | テバ ファーマシューティカル インダストリーズ リミティド | カルベジロール |
| IL156315A0 (en) | 2000-12-07 | 2004-01-04 | Cv Therapeutics Inc | Abca-1 elevating compounds |
| HU229403B1 (en) * | 2000-12-18 | 2013-12-30 | Actelion Pharmaceuticals Ltd | Novel sulfamides and their use as endothelin receptor antagonists |
| FR2819720B1 (fr) | 2001-01-22 | 2004-03-12 | Fournier Lab Sa | Nouveaux comprimes de fenofibrate |
| KR20030041577A (ko) | 2001-11-20 | 2003-05-27 | 디디에스텍주식회사 | 난용성 약물과 치환된 시클로덱스트린을 함유하는고체분산체 및 이를 함유하는 약제학적 조성물 |
| KR20100090726A (ko) | 2002-02-26 | 2010-08-16 | 아스트라제네카 아베 | 수용성 셀룰로스 유도체를 포함하는 이레사의 약학 조제물 |
| JP4769460B2 (ja) * | 2002-12-02 | 2011-09-07 | アクテリオン ファーマシューティカルズ リミテッド | 新規スルファミド類 |
| HRP20050675A2 (en) | 2003-02-25 | 2005-10-31 | Eli Lilly And Company | Crystalline non-solavated 1-(4-(2-piperidinylethoxy)phenoxy)-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene hydrochloride |
| PT1928409E (pt) | 2005-09-12 | 2012-11-27 | Actelion Pharmaceuticals Ltd | Composição farmacêutica estável que compreende uma pirimidina-sulfamida |
| AR062501A1 (es) | 2006-08-29 | 2008-11-12 | Actelion Pharmaceuticals Ltd | Composiciones terapeuticas |
| US8541433B2 (en) | 2008-02-20 | 2013-09-24 | Actelion Pharmaceuticals, Ltd. | Combination comprising macitentan and paclitaxel for treating multi-drug resistant ovarian cancer |
| LT2315587T (lt) | 2008-08-13 | 2018-01-10 | Actelion Pharmaceuticals Ltd. | Terapinės kompozicijos, turinčios macitentano |
-
2008
- 2008-02-07 MX MX2010001837A patent/MX2010001837A/es active IP Right Grant
- 2008-08-14 AR ARP080103552A patent/AR070018A1/es not_active Application Discontinuation
- 2008-08-15 BR BRPI0815360A patent/BRPI0815360B8/pt active IP Right Grant
- 2008-08-15 EP EP08807330A patent/EP2190837B1/en active Active
- 2008-08-15 CN CN2008801016796A patent/CN101772494B/zh active Active
- 2008-08-15 SI SI200830785T patent/SI2190837T1/sl unknown
- 2008-08-15 NZ NZ583990A patent/NZ583990A/en unknown
- 2008-08-15 AU AU2008290234A patent/AU2008290234B2/en active Active
- 2008-08-15 MY MYPI20100680 patent/MY152281A/en unknown
- 2008-08-15 JP JP2010520674A patent/JP5323075B2/ja active Active
- 2008-08-15 RU RU2010109543/04A patent/RU2485116C2/ru active
- 2008-08-15 PT PT08807330T patent/PT2190837E/pt unknown
- 2008-08-15 CA CA2695511A patent/CA2695511C/en active Active
- 2008-08-15 TW TW097131323A patent/TWI411437B/zh active
- 2008-08-15 ES ES08807330T patent/ES2394584T3/es active Active
- 2008-08-15 HR HRP20120878AT patent/HRP20120878T1/hr unknown
- 2008-08-15 DK DK08807330.9T patent/DK2190837T3/da active
- 2008-08-15 WO PCT/IB2008/053282 patent/WO2009024906A1/en not_active Ceased
- 2008-08-15 PL PL08807330T patent/PL2190837T3/pl unknown
- 2008-08-15 KR KR1020107004945A patent/KR101528946B1/ko active Active
- 2008-08-15 US US12/673,413 patent/US8324232B2/en active Active
-
2010
- 2010-02-14 IL IL203936A patent/IL203936A/en active IP Right Grant
- 2010-03-12 MA MA32692A patent/MA31702B1/fr unknown
- 2010-03-16 ZA ZA2010/01872A patent/ZA201001872B/en unknown
-
2012
- 2012-10-25 CY CY20121101015T patent/CY1113255T1/el unknown
-
2024
- 2024-11-27 HU HUS2400041C patent/HUS2400041I1/hu unknown
- 2024-12-02 FI FIC20240041C patent/FIC20240041I1/fi unknown
- 2024-12-03 NO NO2024053C patent/NO2024053I1/no unknown
- 2024-12-04 CY CY2024031C patent/CY2024031I2/el unknown
- 2024-12-04 LT LTPA2024534C patent/LTPA2024534I1/lt unknown
- 2024-12-05 FR FR24C1047C patent/FR24C1047I2/fr active Active
- 2024-12-10 NL NL301304C patent/NL301304I2/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0815360A2 (pt) | Composto derivado de 4-pirimidinossulfamida, composição farmacêutica que o contem, uso e processo para pa preparação do composto | |
| BRPI0815190A2 (pt) | Composto derivado de piridina, composição farmacêutica que o compreende e uso do mesmo | |
| BRPI0819218A2 (pt) | Métodos, estojos e composições para administração de compostos farmacêuticos | |
| BRPI0918359A2 (pt) | composto, composição agroquímica, uso da composição agroquímica e método para preparação do composto | |
| BRPI0813237A2 (pt) | Composto, método para preparar o composto, composição, medicamento, e, uso do composto. | |
| BRPI0818533A2 (pt) | composto, composição farmacêutica, e, processo para a preparação de um composto | |
| BRPI0821004A2 (pt) | Composto derivado de aminopirazol, composição farmacêutica que o contem e uso deste | |
| BRPI0617159A2 (pt) | COMPOSTOS DE PIRIDOPIRIMIDINONE INIBIDORES DE PI3Ka, COMPOSIÇÕES QUE OS CONTEM E PROCESSO PARA PREPARO | |
| BRPI0922475A2 (pt) | composto, composição farmacêutica , método para tratar câncer, e, uso de um composto. | |
| BRPI0818804A2 (pt) | Composto derivado de pirimidina, composição farmacêutica que o compreende e uso desse composto. | |
| BRPI0816331A2 (pt) | Composto, uso de um composto, composição farmacêutica, e, processo para preparar um composto. | |
| BRPI0822946A2 (pt) | Derivado de carboxiamida, processo para preparação de derivado de carboxiamida, composição farmacêutica e uso do derivado de carboxiamida | |
| BRPI0611956A2 (pt) | composto, uso do mesmo, composição farmacêutica, e, processo para preparar um composto | |
| BRPI0811635A2 (pt) | Compostos de arilazol-2-il cianoetilamino, métodos para fazê-los e métodos para o uso dos mesmos | |
| BRPI0812851A2 (pt) | Composto, composição farmacêutica, métodos para o tratamento de uma doença e de uma condição em um indivíduo, processo para preparar um composto, e, uso de um composto | |
| BRPI0814611A2 (pt) | Composição, processo para preparar uma composição, e, uso de uma composição | |
| BRPI0815405A2 (pt) | Compostos derivados de purina, processo para a preparação de uma composição farmacêutica e uso dos mesmos | |
| BRPI0814308A2 (pt) | Processo para o preparo de um complexo solúvel de composto resveratrol e ciclodextrina, complexo composto resveratrol e ciclodextrina, composição nutracêutica, composição farmacêutica, e uso do referido complexo | |
| BRPI0922233A2 (pt) | compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas. | |
| BRPI0820673A2 (pt) | Formulações e composições farmacêuticas de fenilefrina para absorção transmucosal | |
| BRPI0818459A2 (pt) | Composição farmacêutica adequada para uso oftálmico. | |
| BRPI0917661A2 (pt) | produto que contém macitentan, composição farmacêutica que o contém e uso de macitentan | |
| BRPI0912539A2 (pt) | composto, composição farmacêutica , método para tratar uma doença, e, uso do composto. | |
| BRPI0914371A2 (pt) | "composto, composição farmacêutica, uso de um composto, método para tratar um indivíduo, e produto de combinação" | |
| BRPI0907892A2 (pt) | Composto antibiótico azatricíclico, medicamento, composição farmacêutica que o contém e uso do mesmo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: IDORSIA PHARMACEUTICALS LTD (CH) |
|
| B25L | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled |
Owner name: ACTELION PHARMACEUTICALS LTD (CH) |
|
| B25C | Requirement related to requested transfer of rights |
Owner name: ACTELION PHARMACEUTICALS LTD (CH) |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: IDORSIA PHARMACEUTICALS LTD (CH) |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/12/2018, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/08/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |